| DB ID | MyCo_5466 |
| Title | Galactomannan testing and Aspergillus PCR in same-day bronchoalveolar lavage and blood samples for diagnosis of invasive aspergillosis |
| Year | 2016 |
| PMID | 27744310 |
| Fungal Diseases involved | Invasive aspergillosis |
| Associated Medical Condition | None |
| Genus | Aspergillus |
| Species | spp. |
| Organism | Aspergillus spp. |
| Ethical Statement | The study protocol was approved by the local ethics committees,Medical University Graz, Austria (EC-numbers 25–221 and 23– 343) and Mannheim University Hospital, Germany (ECnumber 2012–320N-MA) and registered at ClinicalTrials. Gov (Identifier: NCT02058316 and NCT01576653). |
| Site of Infection | None |
| Opportunistic invasive | Opportunistic |
| Sample type | Body fluid |
| Sample source | Blood |
| Host Group | Human |
| Host Common name | Human |
| Host Scientific name | Homo sapiens |
| Biomarker Name | GM |
| Biomarker Full Name | Galactomannan |
| Biomarker Type | Diagnostic |
| Biomolecule | Protein |
| Geographical Location | Austria |
| Cohort | This analysis of prospectively collected data comprised 53 paired routine BALF and blood samples obtained at the same day from 53 adult immunocompromised patients. A total of 38 patients with hematological malignancies undergoing bronchoscopy were prospectively enrolled at the Medical University of Graz, Austria, and 15 patients with mixed underlying diseases (12 patients with haematological malignancy and three patients with other underlying diseases) and suspected IA prospectively enrolled at the Mannheim University Hospital. Key inclusion criteria were (i) adult patients with (ii) underlying hematological malignancy (Medical University of Graz) or mixed underlying diseases (Mannheim University Hospital) who were (iii) at risk for IA according to attending clinicians (e.g., febrile neutropenia, induction chemotherapy for acute myeloid leukemia, allogeneic stem cell transplantation) and had (iv) a BALF sample obtained in clinical routine. All patients who met inclusion criteria between April 2014 and November 2015 (at the Medical University of Graz) or between July 2013 and May 2014 (at Mannheim University Hospital) and signed informed consent where included in this analysis. IA was graded in accordance with the revised criteria by the European Organization for Research and Treatment of Cancer Invasive Fungal Infections Cooperative Group (EORTC) and the Mycoses Study Group of the National Institute of Allergy and Infectious Disease (MSG). Patients with possible IA (n = 13, all negative Aspergillus PCR results in BALF and blood), as well as those who did not have GM and PCR results from both BALF and blood (n = 6) were excluded from this analysis. |
| Cohort No. | 53 |
| Age Group | None |
| P Value | None |
| Sensitivity | 0 |
| Specificity | 1 |
| Positive Predictive Value | 0 |
| MIC | None |
| Fold Change | None |
| Pathway | None |
| Disease Introduction Mechanism | Invasive aspergillosis (IA) is an important cause of morbidity and mortality among immunocompromised patients and associated with high mortality rates, especially in the absence of early diagnosis and timely treatment. Clinical signs and symptoms of IA as well as radiological findings are often unspecific in the early phase of disease. In recent years, antigen testing has become one of the cornerstones of invasive fungal infection (IFI) diagnostics. |
| Technique | PCR |
| Analysis Method | Aspergillus PCR |
| ELISA kits | None |
| Assay Data | None |
| Validation Techniques used | ELISA, PCR |
| Up Regulation Down Regulation | Increase |
| Sequence Data | None |
| External Link | None |
